Miracle Drug May Be Ailing Gilead

 | Apr 23, 2014 | 3:48 PM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

gild

,

biib

,

abbv

,

mrk

Is it possible for a drug to be too good? That's what could be "ailing" Gilead (GILD). After the company reported $4.9 billion in sales last night  (a 104% increase, year-over-year), you would expect its shares would be trading much higher today.

Gilead has a miracle drug called Sovaldi that saves the lives of people who have hepatitis C. It's a remarkably potent drug that cures people after a 12-week regimen.

There are three problems with this miracle achievement though. First, it costs $84,000 and the insurers are balking even though the consequences of not treating hepatitis C are far worse not just for the patient, of course, but for the insurers themselves.

Second, Wall Street likes maintenance drugs that you take for the rest of your life, like the anti-cholesterol drugs or the multiple sclerosis drugs (including Biogen Idec's (BIIB), although that stock is down today), which are annuity streams. Once you are cured of hepatitis C you are cured -- and you have to believe that, even though only half of the doctors who can prescribe it, according to Gilead, have already. So, there is a real (albeit high quality) finite problem.

Third, there is competition coming from both AbbVie (ABBV) and Merck (MRK). Normally, I would say that Gilead's got first-move advantage and you don't need to worry, the other guys are making real progress and if their products are as good as Sovaldi, believe me, that $84,000 price tag won't stay up there.

All that said, I really like Gilead. It has more than Sovaldi going for it. It's got a terrific balance sheet and can buy back stock with abandon. But these outlined woes, the idea that there is big inventory in the system and this market's newfound hatred of biotech will keep a lid on this stock for some time.

After the great start for this hepatitis C cure, this situation is frustrating. But sometimes companies develop products that are too amazing for their own good and the good of their shareholders -- even though they are certainly fabulous for the customers.

Columnist Conversations

HON has had a powerful recovery off last Wednesday's spike low. After taking an ugly spill off the Septe...
Recent spin-off Knowles Corp (KN) has been blasted since pre-announcing a bad quarter which be made official n...
On October 13th, I suggested it was time to buy iRobot (IRBT) noting that it was being "squeezed" and there wa...
For those involved in the long FCG trade discussed here in CC, and in the Trader Daily, I just cut roughly a 1...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.